AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03811197 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telemedicine
Description: All subjects received an additional dietary counseling for 6 months (via internet, messenger or telephone) two weeks after each standard visit will be added to the counseling (Part A). Standard and additional dietary counseling (T) are provided by a trained dietitian. Months 9 and 12 - follow up (Part B).
Study NCT03811197 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnotic Suggestions
Description: All subjects received individual hypnotic suggestion (HS) for 6 months as a supplementary method for dietary counseling. HS will be adapted to the small steps method used in the management of obesity. During the visit, HS will be recorded and the individual will listen to it every day (Part A). HS will be provided by a physician, qualified in the field of hypnotherapy. Months 9 and 12 - follow up (Part B).
Study NCT03742674 — intervention group
Intervention type: OTHER
Intervention: Follow up
Description: No intervention
Study NCT01475188 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allergovit
Description: commercially available grass pollen allergoid (100%), concentration A (1000 TU/ml, therapeutic units/ml)concentration B (10000 TU/ml).Patients were given subcutaneous injections with initial dose of 0.1 ml (concentration A) was increased once a 7 (+7) days until the highest tolerated dose (0.6, concentration B) was reached and SIT was continued with injections once every 4 - 6 weeks up to two years.
Study NCT01475188 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo administered with the same scheme and doses as specific subcutaneous immunotherapy
Study NCT00510549 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modality: Peritoneal Dialysis
Description: Peritoneal Dialysis: CAPD; Hemodialysis: 3 times/week
Study NCT03945565 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fraction of inspired oxygen level
Description: A fraction of inspired oxygen level during off-pump coronary artery bypass grafting will be set differently between the study groups: 0.3 vs 0.8.
Study NCT04430270 — intervention group
Intervention type: BEHAVIORAL
Intervention: Survey
Description: Sequential Assignment
Study NCT03563950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Specified dose on specified days
Study NCT03563950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986224
Description: Specified dose on specified days
Study NCT03613454 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Splenic artery embolization with vascular embolic plugs
Description: Splenic artery embolization with vascular embolic plugs
Study NCT01511744 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated influenza split vaccine
Description: 3000 participants (750 of above 60,750 of age 19-60, 750 of age 13-18 and 750 of age 3-12) to receive influenza split vaccine of 15 μg HA; one dose regime
Study NCT05774418 — intervention group
Intervention type: BIOLOGICAL
Intervention: BNT162b2 COVID-19 Vaccine
Description: BNT162b2 is a vaccine for preventing coronavirus disease 2019 (COVID-19) in people from the age of 18 years. BNT162b2 contains tozinameran, a messenger RNA (mRNA) molecule with instructions for producing a protein from the original strain of SARS-CoV-2, the virus that causes COVID-19. BNT162b2 is given as two injections, usually into the muscle of the upper arm, 3 weeks apart.
Study NCT00005615 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interferon alfa
Description: Interferon alfa as outlined in treatment arm.
Study NCT00005615 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Radiation therapy as outlined in treatment arm.
Study NCT03232528 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Herb-partitioned moxibustion
Description: Patients receive herb-partition moxibustion 3 times a week, once a day for 30 minutes, for a total of 12 weeks.
Study NCT03232528 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham herb-partitioned moxibustion
Description: Patients receive sham herb-partition moxibustion 3 times a week, once a day for 30 minutes, for a total of 12 weeks.
Study NCT02060656 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: 1000mg/m2 IV D1, D8, D15 every 28 days
Study NCT02060656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000mg/m2 IV D1, D8, D15 every 28 days
Study NCT02060656 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: 1000mg/m2 IV or PO D1-5 every 28 days
Study NCT02060656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: 1000mg/m2 IV or PO D1-5 every 28 days
Study NCT02060656 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: 375mg/m2 IV D1, D15 every 28 days
Study NCT02060656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375mg/m2 IV D1, D15 every 28 days
Study NCT02060656 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 100mg/m2 IV D15 every 28 days
Study NCT02060656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 25mg PO D1-21 every 28 days
Study NCT05508451 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Double jaw surgery
Description: A type of orthognathic surgery
Study NCT05508451 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Double jaw surgery
Description: A type of orthognathic surgery
Study NCT04123041 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: JUUL ENDS, Combustible cigarette, comparator e-cigarette, Nicorette gum
Description: JUUL ENDS and comparator e-cigarette will be used for 5 minutes ad libitum, one combustible cigarette will be used ad libitum, Nicorette gum will be used for 30 minutes ad libitum
Study NCT00002806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lomustine
Study NCT00002806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: procarbazine hydrochloride
Study NCT00002806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Study NCT00002806 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-LET photon therapy
Study NCT02129244 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NCM-Plus
Description: The NCM will follow the domains of the chronic care model by:~1. Assuring effective, efficient clinical care and self-management support~2. Promoting clinical care consistent with scientific evidence and patient preferences~3. Organizing data to facilitate efficient, effective care~4. Empowering and preparing patients to manage their health and health-care needs~5. Mobilizing community resources to meet the needs of patients
Study NCT04156581 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Bupivacaine is administered typically to reduce sensation in an area. It acts as a nerve block for surgical procedures.
Study NCT04156581 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone is a corticosteroid that reduces inflammation.
Study NCT04156581 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline is a mixture of NaCl and water that can be used as a placebo.
Study NCT00657618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Stibogluconate (SSG)
Description: 100 mg/ml/vial. Treatment for laboratory-confirmed leishmaniasis with SSG 20mg/kg/d intravenously (IV) for 10 days or 20 days; visceral leishmaniasis will be treated with SSG 20mg/kg/d IV for 28 days as a second line of therapy for those failing or intolerant of Ambisome; and mucosal leishmaniasis will be treated with SSG 20mg/kg/d IV for 28 days.
Study NCT03704376 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 30 ml of 0.2% ropivacaine
Study NCT03704376 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 15 ml of 0.2% ropivacaine
Study NCT03704376 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 100 mcg clonidine
Study NCT03704376 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High-frequency linear ultrasound transducer
Study NCT01865370 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Kochujang Pills
Description: Kochujang Pills (34.5g/day)
Study NCT01865370 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (34.5g/day)
Study NCT01445938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR97276A
Description: Pharmaceutical form:solution for injection~Route of administration: intramuscular
Study NCT01445938 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: arthemeter + lumefantrine (ACTs)
Description: Pharmaceutical form:tablet~Route of administration: oral
Study NCT01405950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanaflex Capsules
Description: 0.025 mg/kg
Study NCT01405950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanaflex Capsules
Description: 0.05 mg/kg
Study NCT04680455 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online home-based strength training
Description: Body weight exercises (i.e., squats, tricep dips, lunges, and push-ups) delivered online through Teams
Study NCT00489970 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Taking of blood samples
Description: No treatment is planned to be given in this study. Blood samples will be collected at the following time points: 1 year, 3 years, 5 years and 9 years after the dose of vaccination.
Study NCT00489970 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Taking of blood samples
Description: No treatment is planned to be given in this study. Blood samples will be collected at the following time points: 1 year, 3 years, 5 years and 9 years after the dose of vaccination.
Study NCT00489970 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Boostrix
Description: A single dose of Boostrix was administered in the primary study (NCT00346073). No treatment was given in this study.
Study NCT00489970 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Boostrix
Description: A single dose of Boostrix was administered in the primary study (NCT00346073). No treatment was given in this study.
Study NCT00489970 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adacel
Description: A single dose of Adacel was administered in the primary study (NCT00346073). No treatment was given in this study.
Study NCT03870750 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive Palliative Care
Description: focuses on relieving symptoms of stress from serious illness and care through physical, cultural, psychological, social, spiritual, and ethical aspects
Study NCT03870750 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Management
Description: physical exercise, strength training, stress reduction, medication management, dietary recommendations, and education
Study NCT03870750 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Given standard of care
Study NCT03870750 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo HCT
Study NCT03870750 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03870750 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03870750 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03870750 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03870750 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Complete surveys
Study NCT03870750 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Complete surveys
Study NCT04334668 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oral Sodium Chloride
Description: Subjects will be randomized to receive 2 grams oral Sodium Chloride three times daily with meals for approximately 4 days
Study NCT04334668 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be randomized to receive a placebo three times daily with meals for approximately 4 days.
Study NCT03320070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acthar Gel
Description: Acthar Gel for subcutaneous (SC) injection (80 units per 1 mL)
Study NCT03320070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo gel for SC injection
Study NCT02358603 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Chronotropic Incompetence Diagnostic Algorithm
Study NCT02358603 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Chronotropic Incompetence Diagnostic Algorithm
Study NCT05166408 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Buccinator myomucosal flap
Description: Buccinator myomucosal flap for primary cleft palate palatoplasty
Study NCT05166408 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Bardach two flap palatoplasty
Description: Bardach two flap palatoplasty
Study NCT01205594 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ITPR
Description: the ITPR will be inserted in the anesthesia circuit and activated to provide -10 mmHg ETP.
Study NCT01912612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Subjects will receive 30 mg duloxetine orally for 7 days, then 60 mg duloxetine orally for 28 days, then 30 mg duloxetine orally x 14 days.
Study NCT01089426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omegaven™
Description: 1 g/kg/d of Omegaven until discontinuation of PN
Study NCT02646644 — intervention group
Intervention type: OTHER
Intervention: Metastasized intestinal NET
Description: This is an observational study
Study NCT00659971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAC113
Description: PAC113 mouthrinse 0.15%; 0.075%; 0.0375% QID for 14 days
Study NCT00659971 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PAC113
Description: PAC113 mouthrinse 0.15%; 0.075%; 0.0375% QID for 14 days
Study NCT00347958 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus-diphtheria-acellular pertussis (Tdap) vaccine
Description: 0.5mL, Intramuscular (IM)
Study NCT03688867 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prehabilitation regimen
Description: The intervention targets individual behavior, specifically a patient's proclivity to exercise prior to pancreatic resection. The prehabilitation program is tailored to the three most commonly used objective frailty metrics currently available and will be implemented during the initial consultation visit in the surgery outpatient clinic, where patients will undergo baseline testing and then provided with a fitness tracker and stress ball.~Additionally, they will be provided with an activity log to keep track of their daily activity. Shown below is the activity log.
Study NCT01569971 — intervention group
Intervention type: OTHER
Intervention: Assessment
Description: In this study, through the use of focus groups and questionnaires, we will identify perceptions of transition from pediatric to adult care, transition readiness, disease knowledge, and self-management skills, and assess components of the St. Jude Children's Research Hospital (SJCRH) Sickle Cell Disease Transition Program. Participants will participate in focus groups to discuss transition and transition-related concepts and evaluate components of the transition program. Additionally, participants will complete questionnaires about specific aspects of the transition program and about current disease knowledge and management skills.
Study NCT02476578 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Email
Description: Automated Email to the primary doctor and nurse, with the details of the patient, the condition found and the relevant measures to consider.
Study NCT00786760 — intervention group
Intervention type: OTHER
Intervention: Cohort: 3000 men examined every 6 months for 4 years.
Description: Prospectively assess HPV infection in a large cohort of men in the US , Mexico, and Brazil representing countries of low and high risk.
Study NCT01089426 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Historical Controls
Description: Standard of Care
Study NCT01921569 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care Therapy
Description: Rest, ice, compression, elevation (RICE), NSAID or salicylate medication for pain, Physical Therapy and stretching exercises, Reduction in impact activities, to include an arm sling.
Study NCT01921569 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard of Care Therapy
Description: Rest, ice, compression, elevation (RICE), NSAID or salicylate medication for pain, Physical Therapy and stretching exercises, Reduction in impact activities, to include an arm sling.
Study NCT01921569 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dHACM Injection
Description: Injection into affected area with micronized dHACM suspended with total volume of 1 cc normal saline.
Study NCT01921569 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline Injection
Description: Injection into affected area with 1.0 cc normal saline solution instead of active agent.
Study NCT03009045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tedizolid
Description: 200mg oral tedizolid one pill per day
Study NCT02434692 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ARGOS-IO system
Description: Implantation of ARGOS-IO pressure sensor after IOL placement within the cataract surgical procedure on day 0 (V01)
Study NCT00786760 — intervention group
Intervention type: OTHER
Intervention: Pilot study: 150 men examined every 6 months for 4 years.
Description: Prospectively assess HPV infection in a large cohort of men in the US , Mexico, and Brazil representing countries of low and high risk.
Study NCT01065337 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: tissue repair cells (TRC)
Description: expanded bone marrow cells enriched in CD90+ mesenchymal stem cells
Study NCT00778648 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Juice Plus
Description: Juice Plus+® is a dietary supplement from concentrated fruits (apple, orange, pineapple,cranberry, cherry (acerola), papaya and peach) and vegetables (carrot, parsley, beet, broccoli, kale, cabbage, spinach, and tomato).~Subjects will take four capsules of Juice Plus+® daily.
Study NCT00778648 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Four capsules of placebo daily.
Study NCT03695172 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Patients will be randomly assigned to receive one three blocks (TAP, QL, ESP)after delivery of baby with ropivicaine
Study NCT03695172 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAP block
Description: Patient will receive bilateral TAP blocks after delivery and within one hour of skin closure with 25 mL of 0.2% ropivacaine with epinephrine 1:400,000 per side.
Study NCT03695172 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: QL block
Description: Patients will receive bilateral QL blocks after delivery and within one hour of skin closure with 25 mL of 0.2% ropivacaine with epinephrine 1:400,000 per side.
Study NCT04310800 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LIFT-plug technique
Description: Small-intestine submucosa extracellular matrix plug was soaked in saline for 5-10 min, then placed into the intersphincteric groove and pulled through the curetted tract to the external opening. The plug was secured with a figure-of-eight 3/0 absorbable suture to the fistula opening in the external sphincter and ligated. Excess plug protruding from the external opening was trimmed flush with the skin without fixation. The wound was loosely closed with 2-3 interrupted 3/0 absorbable sutures
Study NCT01405950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanaflex Capsules
Description: 0.075 mg/kg
Study NCT01405950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanaflex Capsules
Description: 0.1 mg/kg
Study NCT01239056 — intervention group
Intervention type: PROCEDURE
Intervention: Endoscopy
Description: Endoscopic drainage of a pancreatic pseudocyst using a metal stent per medical indication.
Study NCT01065337 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: bone marrow stem cells (BMC)
Description: bone marrow stem cells
Study NCT03695172 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ESP block
Description: Patients will receive bilateral ESP blocks after delivery and within one hour of skin closure with 25 mL of 0.2% of ropivacaine with epinephrine 1:400,000 per side.
Study NCT02172508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium Inhalation Capsule